Gastric Antral Vascular Ectasia and Its Clinical Correlates in Patients with Early Diffuse Systemic Sclerosis in the SCOT Trial
Emily W. Hung(Rheumatology Consultants), Keith M. Sullivan(Duke Medical Center), Sharon Castina(National Institute of Allergy and Infectious Diseases), Shervin Assassi(University of Houston), Maureen D. Mayes(The University of Texas Health Science Center), Victor I. Machicao(The University of Texas Health Science Center at Houston), Roozbeh Sharif(The University of Texas Medical Branch at Galveston), Stephen J. Forman(City Of Hope National Medical Center), Mary Ellen Csuka(Medical College of Wisconsin), Karen K. Ballen(University of Virginia Health System), Chitra Hosing(The University of Texas MD Anderson Cancer Center), Lynette Keyes-Elstein(National Institute of Allergy and Infectious Diseases), Mark H. Wener(University of Washington), Daniel E. Furst(University of California, Los Angeles), Richard A. Nash(Colorado Blood Cancer Institute), Shin Mineishi(University of Alabama at Birmingham), James R. Seibold(University of Michigan), Leslie J. Crofford(Vanderbilt University Medical Center), Dinesh Khanna(University of Michigan), Jan Storek(University of Washington), Robert W. Simms(Dartmouth–Hitchcock Medical Center), Peter A. McSweeney(Mesoblast (United States)), Kristine Phillips(Vanderbilt University), Sharon LeClercq(University of Calgary), Beverly Welch(National Institute of Allergy and Infectious Diseases), Christopher Bredeson, Ellen Goldmuntz(National Institute of Allergy and Infectious Diseases), E. William St. Clair(Duke University)
Cited by 79
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k